#United States #New York #Gross Law Firm #EPIX #ESSA Pharma Inc.

Important Shareholder Notice Regarding ESSA Pharma Inc.

The Gross Law Firm is reaching out to the shareholders of ESSA Pharma Inc. (NASDAQ: EPIX) regarding a significant legal development concerning a class lawsuit. This notice is primarily aimed at those who acquired shares of EPIX during the specified class period, which spans from December 12, 2023, to October 31, 2024. As a shareholder, it is crucial to understand your rights and potential actions in response to allegations made against the company.

Background of the Lawsuit

The lawsuit alleges that ESSA Pharma and its executives issued misleading statements about the drug masofaniten. Specifically, the complaint contends that the company did not adequately disclose that combining masofaniten with enzalutamide does not demonstrate a clear efficacy advantage over using enzalutamide alone. This revelation is concerning because it contradicts previous assertions made by the company regarding the drug's effectiveness in treating prostate cancer.

Key Allegations Include:

1. Claims surrounding the efficacy of masofaniten in combination therapy have been overstated.
2. The M-E Combination Study lacked the likelihood of meeting its primary endpoint as previously described to investors.
3. The assertions made by ESSA Pharma about masofaniten’s clinical prospects misled investors about its market viability leading to inflated stock prices.

Deadline for Lead Plaintiff Applications

The next critical date for shareholders is March 25, 2025. This is the deadline for interested shareholders to register for consideration as a lead plaintiff in the class action lawsuit. Engaging now can ensure that your voice is heard in seeking justice for potential losses incurred.

What Should Shareholders Do?

Interested shareholders are encouraged to contact the Gross Law Firm to learn more about the process of becoming a lead plaintiff. It is essential to act before the specified deadline as participation in the class action does not require one to become a lead plaintiff.

Monitoring Your Investment

Once you register as an EPIX shareholder, you will gain access to portfolio monitoring software provided by the Gross Law Firm. This platform will keep you informed about case developments and other crucial updates throughout the lawsuit's progression.

Why Choose the Gross Law Firm?

The Gross Law Firm has garnered a reputation as a trusted class action law firm dedicated to protecting investor rights against deceptive practices and corporate wrongdoing. Their mission revolves around ensuring that companies are held accountable for misleading their investors, thus promoting good corporate citizenship.

If you have purchased shares of ESSA Pharma during the stipulated period and feel affected by the allegations, now is the time to reach out. Registering is free and does not carry any obligation, but delaying could hinder your ability to seek potential recovery.

Contact Information

For more details, or to register your interest, please visit this link. Alternatively, you can reach out directly to the Gross Law Firm at their New York office or via their provided email and phone number:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Stay vigilant and informed about your investments. The Gross Law Firm is here to assist you in navigating the complexities of this lawsuit and working towards a resolution that aligns with your interests.

• ---